LLY

986.47

-0.29%↓

JNJ

228.5

+1.02%↑

ABBV

208.59

+0.06%↑

UNH

388.01

+0.71%↑

AZN

184.28

+0.75%↑

LLY

986.47

-0.29%↓

JNJ

228.5

+1.02%↑

ABBV

208.59

+0.06%↑

UNH

388.01

+0.71%↑

AZN

184.28

+0.75%↑

LLY

986.47

-0.29%↓

JNJ

228.5

+1.02%↑

ABBV

208.59

+0.06%↑

UNH

388.01

+0.71%↑

AZN

184.28

+0.75%↑

LLY

986.47

-0.29%↓

JNJ

228.5

+1.02%↑

ABBV

208.59

+0.06%↑

UNH

388.01

+0.71%↑

AZN

184.28

+0.75%↑

LLY

986.47

-0.29%↓

JNJ

228.5

+1.02%↑

ABBV

208.59

+0.06%↑

UNH

388.01

+0.71%↑

AZN

184.28

+0.75%↑

Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Gesloten

12.21 -1.21

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

11.78

Max

12.67

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.4M -14M
EPS	-0.15
Werknemers	37
EBITDA	-2.7M -15M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+156.7% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-18M 1.3B
Vorige openingsprijs	13.42
Vorige sluitingsprijs	12.21

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

3.165 / 3.5827 Steun & Weerstand

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 mei 2026, 23:10 UTC

Populaire aandelen

Stocks to Watch: Agilysys, XP

18 mei 2026, 18:44 UTC

Belangrijke Marktbewegers

Claritev Shares Recover After Comments About DOJ

18 mei 2026, 23:55 UTC

Winsten

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 mei 2026, 23:47 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

18 mei 2026, 23:47 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 mei 2026, 23:37 UTC

Marktinformatie

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 mei 2026, 22:31 UTC

Acquisities, Fusies, Overnames

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 mei 2026, 22:30 UTC

Acquisities, Fusies, Overnames

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 mei 2026, 22:30 UTC

Acquisities, Fusies, Overnames

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 mei 2026, 22:25 UTC

Acquisities, Fusies, Overnames

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 mei 2026, 22:24 UTC

Acquisities, Fusies, Overnames

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

18 mei 2026, 20:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

18 mei 2026, 20:25 UTC

Winsten

Correct: XP 1Q Total Client Assets BRL1.53T

18 mei 2026, 20:23 UTC

Winsten

XP 1Q Total Client Assets BRL1.53B

18 mei 2026, 20:19 UTC

Winsten

XP 1Q Adj EPS BRL2.49 >XP

18 mei 2026, 20:19 UTC

Winsten

XP 1Q Rev BRL4.73B >XP

18 mei 2026, 19:10 UTC

Marktinformatie

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 mei 2026, 19:00 UTC

Winsten

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 mei 2026, 18:52 UTC

Marktinformatie

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 mei 2026, 18:17 UTC

Marktinformatie

Acquisities, Fusies, Overnames

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 mei 2026, 17:22 UTC

Marktinformatie

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 mei 2026, 16:57 UTC

Acquisities, Fusies, Overnames

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 mei 2026, 16:57 UTC

Marktinformatie

Global Energy Roundup: Market Talk

18 mei 2026, 16:57 UTC

Marktinformatie

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 mei 2026, 16:54 UTC

Acquisities, Fusies, Overnames

Vinci Doesn't Set Out Financial Details of Deal

18 mei 2026, 16:50 UTC

Acquisities, Fusies, Overnames

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 mei 2026, 16:49 UTC

Acquisities, Fusies, Overnames

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 mei 2026, 16:49 UTC

Acquisities, Fusies, Overnames

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 mei 2026, 16:48 UTC

Acquisities, Fusies, Overnames

Vinci Buys Canada's Modern Group of Companies

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

156.7% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 31.6 USD 156.7%

Hoogste 40 USD

Laagste 27 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

3.165 / 3.5827Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.